Biotech RadarJobs updated

COMPANY

Liquidia

liquidia.com ↗

FDA-approved therapeutic company Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Pulmonary Arterial Hypertension Primary Pulmonary Hypertension Raynaud's Phenomenon Secondary to Systemic Sclerosis Pulmonary Hypertension Interstitial Lung Disease Pulmonary Hypertension Due to Lung Diseases Acute Pain Influenza L606 LIQ861 LIQ001

10Trials (company is sponsor)1FDA records (2 yrs)

Timeline

  1. Trial start Phase 2: A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks source ↗
  2. Trial start Phase 4: A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag source ↗
  3. Trial start 3: A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD source ↗
  4. FDA FDA Original approval: YUTREPIA (treprostinil sodium) — NDA213005, May 23, 2025. Applicant at approval: Liquidia Technologies, Inc. source ↗
  5. Trial start —: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH source ↗
  6. Trial start 3: A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD source ↗
  7. Trial start Phase 2: Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil source ↗
  8. Trial start Phase 3: Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil source ↗
  9. Trial start Phase 3: Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil source ↗
  10. Trial start Phase 1: Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations source ↗
  11. Trial start Phase 1/Phase 2: A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT07759804A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagPhase 4Recruiting2026-092027-05 (estimated)
NCT07285655A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD3RecruitingApr 23, 20262029-07 (estimated)
NCT07748000A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksPhase 2Not yet recruitingOct 26, 20262027-02 (estimated)
NCT06129240An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PHNot listedRecruitingDec 28, 2023Jul 31, 2027 (estimated)
NCT04691154A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD3Active, not recruitingAug 1, 2021Mar 20, 2025 (actual)
NCT03992755Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of TreprostinilPhase 3Active, not recruitingJul 18, 2019May 31, 2025 (estimated)
NCT03399604Investigation of the Safety and Pharmacology of Dry Powder Inhalation of TreprostinilPhase 3CompletedJan 2, 2018May 6, 2019 (actual)
NCT03884465Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of TreprostinilPhase 2TerminatedNov 11, 2019Dec 23, 2020 (actual)
NCT02982889Single Ascending Dose Study of Two Liquidia Bupivacaine FormulationsPhase 1CompletedDec 5, 2016Mar 23, 2017 (actual)
NCT01224262A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001Phase 1/Phase 2Completed2010-092011-12 (actual)

FDA records (last 2 years)

Feedback